Synapse - Advanced Practice Providers

Results (95)

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial

Journal Article

Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Journal Article

Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
Blood (2020)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
Blood (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
Blood (2020)

Fulltext@MSK | Save

Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Meeting Abstract

Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
Blood (2020)

Fulltext@MSK | Save

International prognostic index predicts outcomes in patients with relapsed and refractory large diffuse B cell lymphoma treated with commercial CAR T cells

Meeting Abstract

Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Roni, S.; Batlevi, Y.; Silverberg, M. L.; Batlevi, C. W.; Brentjens, R.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)

Meeting Abstract

O'Cearbhaill, R. E.; Park, J. H.; Halton, E. F.; Diamonte, C. R.; Mead, E.; Lakhman, Y.; Kane, P.; Riviere, I. C.; Brentjens, R. J.
Gynecologic Oncology (2020)

Fulltext@MSK | Save

Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant

Journal Article

Fabrizio, V. A.; Kernan, N. A.; Boulad, F.; Cancio, M.; Allen, J.; Higman, M.; Margossian, S. P.; Mauguen, A.; Prockop, S.; Scaradavou, A.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save